Vascepa is a prescription medication with two FDA-approved uses: lowering the risk of cardiovascular events in people already at high risk, and reducing dangerously high triglyceride levels. It contains a highly purified form of EPA, one of the omega-3 fatty acids found in fish, but in a concentrated pharmaceutical grade that works differently from over-the-counter fish oil supplements.
Reducing Cardiovascular Risk
The primary use of Vascepa is reducing the risk of heart attack, stroke, unstable angina requiring hospitalization, and the need for procedures to reopen blocked coronary arteries. This indication applies to adults who are already on the maximum tolerated dose of a statin and still have triglyceride levels at or above 150 mg/dL, along with either established cardiovascular disease or diabetes plus two or more additional heart disease risk factors.
This cardiovascular indication came from a landmark trial called REDUCE-IT, which enrolled over 8,000 patients and tracked them for nearly five years. The results were striking: the rate of major cardiovascular events dropped from 22% in the placebo group to 17.2% in the Vascepa group, a 25% relative reduction. Heart attacks specifically fell from 12% to 8.6%. The combination of cardiovascular death or heart attack occurred in 9.6% of the Vascepa group compared to 12.4% on placebo. These benefits appeared on top of what patients were already getting from statin therapy, which is why the FDA approved Vascepa as an add-on rather than a standalone treatment.
The cardiovascular protection Vascepa provides goes beyond simply lowering triglycerides. While the exact mechanisms are still being studied, the benefits seen in the REDUCE-IT trial were larger than what triglyceride reduction alone would predict, suggesting the drug may also reduce inflammation in blood vessels and stabilize arterial plaques that could otherwise rupture and cause a heart attack or stroke.
Lowering Severe Triglyceride Levels
Vascepa’s second approved use is for adults with severe hypertriglyceridemia, defined as triglyceride levels at or above 500 mg/dL. At these levels, triglycerides pose a direct health threat beyond heart disease: extremely high levels can trigger acute pancreatitis, a painful and potentially dangerous inflammation of the pancreas. For this use, Vascepa is prescribed alongside dietary changes to bring triglycerides down into a safer range. That said, the FDA notes that the drug’s specific effect on pancreatitis risk in this population has not been formally determined.
Normal triglyceride levels fall below 150 mg/dL. Levels between 150 and 499 are considered elevated to high, while anything at or above 500 is classified as severe. If your levels are in the severe range, your doctor will likely recommend aggressive dietary changes (cutting refined carbs, sugar, and alcohol) alongside medication.
How Vascepa Differs From Fish Oil Supplements
Vascepa contains only EPA in a purified ethyl ester form. This is a critical distinction from most fish oil supplements sold over the counter, which contain a mix of EPA and DHA, the two main omega-3 fatty acids. Vascepa actually lowers DHA levels slightly (by about 3.3% in clinical comparisons), reinforcing that it works through a different pathway than general omega-3 supplementation.
The purity matters for several reasons. Over-the-counter fish oil capsules vary widely in their actual omega-3 content, and some contain saturated fat or oxidized oils. Vascepa delivers a standardized, consistent dose of EPA with each capsule. Large trials of mixed omega-3 supplements have generally not shown the same cardiovascular benefits that Vascepa demonstrated in REDUCE-IT, which is why major cardiology guidelines specifically reference icosapent ethyl (Vascepa’s active ingredient) rather than fish oil broadly.
How It Is Taken
The standard dose is 4 grams per day, split into two doses of two capsules each, taken with food. All clinical trials administered the drug with or after meals, so taking it on an empty stomach is not recommended. The capsules are swallowed whole.
Because Vascepa is designed to work alongside other treatments, most people taking it for cardiovascular risk reduction will continue their statin and any other heart medications. It is not a replacement for statins but an additional layer of protection for people whose risk remains elevated despite cholesterol-lowering therapy.
Who Is a Good Candidate
For the cardiovascular indication, Vascepa fits a specific patient profile: someone already taking a statin at the highest dose they can tolerate, with triglycerides still at 150 mg/dL or above, and who either has known heart disease or has diabetes combined with multiple cardiovascular risk factors such as high blood pressure, smoking history, or a family history of early heart disease.
For the triglyceride-lowering indication, the threshold is higher. You would typically be considered if your triglycerides are 500 mg/dL or above despite dietary efforts, regardless of whether you have established heart disease. At these levels, the immediate goal is reducing the risk of pancreatitis and bringing lipid levels closer to a manageable range.
People with known allergies to fish or shellfish should discuss this with their prescriber, since the drug is derived from fish oil. Common side effects in clinical trials included joint pain and swelling in the arms or legs, though serious side effects were uncommon. Some patients experienced a slightly higher rate of atrial fibrillation (an irregular heart rhythm), which is something your cardiologist would monitor if you have risk factors for that condition.